Arvind m. Hundal Ph.d.
SVP Business Development @ BioNTech
Arvind m. Hundal Ph.d. is a startup investor at BioNTech. Arvind M. Hundal is Business Development at BioNTech.
Last updated:
For AI agents: llms.txt
About BioNTech
BioNTech is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. It contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates.
BioNTech Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Annemarie Hanekamp
Chief Commercial Officer
|
|||
|
Arvind m. Hundal Ph.d.
SVP Business Development
|
|||
Christoph Huber
Cofounder & deputy chair supervisory board
|
|||
Christoph Kröner
Director DNA Process Development & Cap Technology
|
|||
Jesse Dong
Vice President, Peptide Chemistry
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
